Why Synthetic Data is the Antidote to Clinical Trials
To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis.
It’s Time to Put Guardrails on GLP-1 Compounding
Consumers are inundated with false information circulating online about GLP-1 medicines, which causes confusion and can lead to potentially serious health problems resulting from dosing errors and adverse reactions to ingredients in compounded GLP-1 products.
presented by
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
AI Drug Discovery Is Reshaping Longevity Medicine. Is Your Practice Ready?
More therapeutic options times more data per option times the same number of clinical hours equals something that breaks. The practices that will thrive when the next wave of longevity therapeutics arrives are the ones that have already solved this.
AI Won’t Replace Clinical Trial Teams, But It Fixes the Bottlenecks That Keep Patients Out
We don’t have a shortage of willing patients — instead we have a shortage of scalable ways to identify and engage them responsibly. AI, used meaningfully offers a reliable path forward.
Real-World Evidence Meets Machine Learning: What It Takes to Future-Proof Evidence Generation
Every life sciences organization needs to consider how best to apply machine learning (ML) to RWE to support better patient outcomes. Here’s how they can ensure RWE is “ML-ready.”
The Lethal Cost of Regulatory Perfection in Rare Disease
Congress has already granted the FDA flexibility in evaluating therapies for rare diseases, including the use of real-world evidence and natural history data when traditional large-scale trials are not feasible. The question before the FDA now is not if those tools can be applied – they can – but if the agency has the courage to use them before more patients lose their autonomy, and ultimately, their lives, to rare disease.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
An AI Driven Approach to Address the Non-Responder Gap in Radiopharmaceutical Therapy
The non-responder gap matters for two reasons: First, patients who are in an advanced stage of cancer lose valuable time in ineffective therapy. Second, it increases the cost of therapy and resources for both patients and the broader healthcare ecosystem.
In the Absence of Objective Measures for ALS, Caregivers are the Only Witnesses. We Shouldn’t Have To Be.
The way we measure ALS progression is failing patients. We are entering a new era of ALS therapeutics but still relying on the same blunt instruments of measurement.
Addressing the 58% Launch Failure Rate: Accelerating Market Access Through Intelligent Decision-Making
Here are some of the structural and strategic causes behind that failure rate, and ways to improve launch outcomes.
Blinded by Science: The Importance of RWD and Post-market Surveillance
When applied with a rigorous, subject-matter-expert guided process, AI-currated RWD is an essential resource giving life science organizations new power to monitor the diverse variety of ways drugs are actually utilized post-approval.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
PGx Testing: Specialists Benefit From, and Build Upon Oncology’s Success
Some specialties, like oncology, have been quicker to embrace the promise of pharmacogenomics (PGx), and their successes can serve as a roadmap as others explore the impact it can have on quality, outcomes and patient satisfaction.
Moving Beyond the Mega-Factory: Why the Future of Biomanufacturing is Agile, Distributed, and Resilient
Personalized and highly-targeted therapeutics are becoming more common, making local or regional production increasingly valuable for faster patient access. This underscores how a hybrid network combining large, centralized plants coupled with flexible regional sites will define the next era of resilient biomanufacturing.
Harnessing RWE for Post-Pandemic Healthcare: Accelerating Drug Development with Real-World Data
As RWE continues to influence the future of drug development, pharma companies will inevitably encounter hurdles. But with the right approach, they can be overcome to unlock critical insights and bring better therapies to patients faster.
The Pill Patients Saved
It reduced cravings, dulled alcohol’s “buzz,” and carried no risk of addiction. By every measure, naltrexone should have immediately become a major triumph. Instead, it flopped because the institutions charged with treating addiction refused to use it. Now considered a gold standard, it survived because patients and communities kept it alive.
Digital Innovation in Pharma: What Will 2026 Bring?
This year will be the turning point from AI “hype” to the adoption of meaningful AI and digital health solutions in pharma. Here four predictions.